Selincro

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Die 51-jährige Patientin nahm erstmalig Nalmefen (Selincro®) vor Besuch eines Festes ein. Eine Viertelstunde nach der Einnahme… (More)
Is this relevant?
2016
2016
BACKGROUND AND PURPOSE The opioid antagonist nalmefene (selincro®) was approved for alcohol-related disorders by the European… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
AIMS To characterize a contemporaneous cohort of UK general practice patients with alcohol use disorder and describe their… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2015
2015
Case 1 A 43-year-old man was brought by ambulance to the emergency department (ED) with severe agitation and clinical signs of… (More)
Is this relevant?
Review
2015
Review
2015
As part of its single technology appraisal process, the National Institute for Health and Care Excellence (NICE) invited the… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
Is this relevant?
2015
2015
Nalmefene (Selincro®) is a selective opioid receptor antagonist, licensed in April 2014 in Switzerland for the reduction of… (More)
Is this relevant?
Review
2014
Review
2014
  • Journal de pharmacie de Belgique
  • 2014
 
Is this relevant?
2014
2014
  • Drug and therapeutics bulletin
  • 2014
The burden of morbidity and mortality resulting from alcohol dependence is high. World Health Organization (WHO) figures suggest… (More)
Is this relevant?
Review
2013
Review
2013
The opioid system modulator nalmefene (Selincro®) is approved in the EU for as-needed use to reduce alcohol consumption in… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?